The positive Phase 3 data strengthens the case for FDA approval. Traders should watch for NDA submission and FDA acceptance in mid-2026, which could be a major catalyst. However, the stock already reflects some optimism given $637M market cap.
Price Chart
Executive Summary
Monopar presented new Phase 3 FoCus analyses showing ALXN1840 significantly improved neurologic and global clinical outcomes vs standard of care in Wilson disease patients, with a favorable safety profile. The data supports the planned mid-2026 NDA submission to the FDA.
Key Facts
- ALXN1840 showed significant neurologic improvement on UWDRS Part III (p=0.006) vs SoC (p=0.435) in Phase 3 FoCus trial
- Global clinical improvement (CGI-I) at Week 48 significantly greater with ALXN1840 vs SoC (p<0.001)
- Safety profile: 266 patients, median treatment 2.58 years, drug-related SAEs 4.9%, no treatment-related deaths
- Monopar plans NDA submission to FDA for ALXN1840 in mid-2026
Financial Impact
No financial data provided; clinical-stage biotech with no approved products
Risk Factors
- Regulatory risk: FDA may request additional data or reject NDA
- Competition from existing Wilson disease therapies
- Need for additional financing to support commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021832 |
| Exhibit: ex_981579.htm | 0001437749-26-021832 |
| Document: 0001437749-26-021832-index-headers.html | 0001437749-26-021832 |
| Document: 0001437749-26-021832-index.html | 0001437749-26-021832 |
| Document: 0001437749-26-021832.txt | 0001437749-26-021832 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $71.84 (+9.71%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | — | $71.84 (−7.86%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $71.84 (−35.82%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $71.84 (−35.79%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | — | $71.84 (−36.83%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $71.84 (−36.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers